Clinical Trials · NCT06131437
A Research Study to See How Well CagriSema Compared to Tirzepatide Helps People With Obesity Lose Weight
- Phase
- Phase 3
- Recruitment status
- Completed
- Sponsor
- Novo Nordisk A/S
- Enrollment
- 809
- Start date
- Nov 2023
- Locations
- 46 sites, United States
- Primary endpoint
- To confirm non-inferiority of CagriSema versus tirzepatide: Relative change in body weight